| Literature DB >> 29184130 |
A V Maslennikova1,2, M A Sirotkina3, A A Moiseev1,4, E S Finagina1, S Y Ksenofontov4, G V Gelikonov1,4, L A Matveev1,4, E B Kiseleva1, V Y Zaitsev1,4, E V Zagaynova1, F I Feldchtein1, N D Gladkova1, A Vitkin1,5.
Abstract
Mucositis is the limiting toxicity of radio(chemo)therapy of head and neck cancer. Diagnostics, prophylaxis and correction of this condition demand new accurate and objective approaches. Here we report on an in vivo longitudinal monitoring of the oral mucosa dynamics in 25 patients during the course of radiotherapy of oropharyngeal and nasopharyngeal cancer using multifunctional optical coherence tomography (OCT). A spectral domain OCT system with a specially-designed oral imaging probe was used. Microvasculature visualization was based on temporal speckle variations of the full complex signal evaluated by high-pass filtering of 3D data along the slow scan axis. Angiographic image quantification demonstrated an increase of the vascular density and total length of capillary-like-vessels before visual signs or clinical symptoms of mucositis occur. Especially significant microvascular changes compared to their initial levels occurred when grade two and three mucositis developed. Further, microvascular reaction was seen to be dose-level dependent. OCT monitoring in radiotherapy offers a non-invasive, convenient, label-free quantifiable structural and functional volumetric imaging method suitable for longitudinal human patient studies, furnishing fundamental radiobiological insights and potentially providing useful feedback data to enable adaptive radiotherapy (ART).Entities:
Mesh:
Year: 2017 PMID: 29184130 PMCID: PMC5705675 DOI: 10.1038/s41598-017-16823-2
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1MIP OCT angiography for monitoring oral mucosal reaction to radiation. Representative svOCT images (a) – before RT; (b) - before visual signs of mucositis appear (after 8 Gy), an increase of vascular density is observed; (c) – grade 1 mucositis (10–12 Gy); (d) – after initiation of anti-mucositis therapy; (e) - grade 2 mucositis (after 14 Gy); (f) – after initiation of anti-mucositis therapy; (g) - grade 3 mucositis (after 20 Gy); (h) - after initiation of anti-mucositis therapy. Corresponding to these 8 representative svOCT image panels, summary statistics from the entire patient cohort are summarized in (i) – average vascular density; and (j) – total length of <15-μm-diameter vessels. In (i,j), data shown are mean ± SD; number of analyzed 3D image data sets and number of patients = 61 and 25 (before RT), 57 and 25 (before visual signs), 19 and 5 (grade 1 mucositis), 21 and 5 (after initiation of anti-mucositis therapy), 20 and 12 (grade 2 mucositis), 24 and 12 (after initiation of anti-mucositis therapy), 21 and 5 (grade 3 mucositis), 22 and 5 (after initiation of anti-mucositis therapy). Blue bar is a peak of symptoms of mucositis; red bar is after initiation of anti-mucositis therapy (see text for details). *Statistically significant difference compared to pre-RT levels (one-tailed t-test, p ≤ 0.05).
Figure 2Changes of oral mucosa microvasculature during IMRT (Case report 1). (a) – Dose distribution, with dose heat maps (hotter colours = higher dose), with arrows indicating the OCT imaging locations; (b) – DVH of PTV and oral mucosa of both cheeks; (c) – vascular density; (d) – total length of <15-μm-diameter vessels. The first clinical symptoms of mucositis occurred at 22 Gy, after which the patient was treated by chamomile and antiseptic washes. Note that both microvascular metrics exhibit significant changes much earlier than the clinical manifestation of mucositis on both cheeks.
Figure 3Changes of microvasculature of oral mucosa throughout the IMRT course (Case report 2). (a) – Dose distribution, with dose heat maps (hotter colors = higher dose, with arrows indicating the OCT imaging locations; (b) – DVH of PTV and oral mucosa of both cheeks: (c) – vascular density; (d) – total length of < 15-μm-diameter vessels. The patient was treated by chamomile and antiseptic washes to combat RT toxicity (after ~16 Gy on the right cheek; left cheek mucositis manifestations were very limited; for details, see text). Note that both microvascular metrics exhibit significant changes much earlier than the clinical manifestation of mucositis on the right cheek.
Patient and radiotherapy characteristics for the examined cohort (n = 25).
|
|
|
| |||
|---|---|---|---|---|---|
| 23 | 2 | ||||
|
| 38–64 | ||||
|
| Oral cavity | Oropharynx | Nasopharynx | ||
| tongue | bottom of the mouth | alveolar ridge | |||
| 8 | 3 | 3 | 8 | 3 | |
|
| I | II | III | IV | |
| 1 | 8 | 9 | 7 | ||
|
| |||||
| Radio(chemo)therapy (curative intent), total dose = 66–70 Gy, 2 Gy fractions | Preoperative radiotherapy, total dose = 46 Gy, 2 Gy fractions | Postoperative radiotherapy, total dose = 50 Gy, 2 Gy fractions | |||
| 21 | 3 | 1 | |||
|
| 5 = IMRT; 20 = 3D conformal | ||||
| Severity of developed mucositis | 3 = grade 0; 5 = grade 1; 12 = grade 2; 5 = grade 3 | ||||
Figure 4Robustness/reproducibility of OCT angiography monitoring at ~ same anatomical sites on the left and right cheeks obtained at three separate measurements (see text for details). (g,h) - quantification of OCT angiographic images: (g) - vascular density; (h) − ≤15 mm-diam vessels length. Data presentes as mean ± SD. No statistically significant differences were found between separate measurements near same anatomical reference points.
Figure 5OCT setup for patient monitoring, with real-time images displayed in the background.